ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $232,651 | -29.8% | 6,526 | -9.2% | 0.00% | -100.0% |
| Q2 2023 | $331,629 | +211.8% | 7,189 | +171.1% | 0.00% | – |
| Q1 2023 | $106,345 | -24.1% | 2,652 | -12.3% | 0.00% | – |
| Q4 2022 | $140,055 | -60.1% | 3,023 | -64.4% | 0.00% | -100.0% |
| Q3 2022 | $351,000 | -29.1% | 8,481 | +2.4% | 0.00% | 0.0% |
| Q2 2022 | $495,000 | -20.8% | 8,281 | -3.8% | 0.00% | 0.0% |
| Q1 2022 | $625,000 | -1.0% | 8,611 | +14.6% | 0.00% | 0.0% |
| Q4 2021 | $631,000 | -57.5% | 7,514 | -54.4% | 0.00% | -66.7% |
| Q3 2021 | $1,485,000 | -1.2% | 16,479 | +4.5% | 0.00% | 0.0% |
| Q2 2021 | $1,503,000 | -33.3% | 15,763 | -20.4% | 0.00% | -40.0% |
| Q1 2021 | $2,254,000 | +9.0% | 19,793 | +32.5% | 0.01% | +25.0% |
| Q4 2020 | $2,067,000 | +497.4% | 14,935 | +253.9% | 0.00% | +300.0% |
| Q3 2020 | $346,000 | +3744.4% | 4,220 | +3771.6% | 0.00% | – |
| Q2 2020 | $9,000 | +350.0% | 109 | +131.9% | 0.00% | – |
| Q1 2020 | $2,000 | 0.0% | 47 | 0.0% | 0.00% | – |
| Q4 2019 | $2,000 | -50.0% | 47 | -54.4% | 0.00% | – |
| Q3 2019 | $4,000 | -63.6% | 103 | -38.3% | 0.00% | – |
| Q2 2019 | $11,000 | 0.0% | 167 | 0.0% | 0.00% | – |
| Q1 2019 | $11,000 | +266.7% | 167 | +169.4% | 0.00% | – |
| Q4 2018 | $3,000 | -70.0% | 62 | -53.4% | 0.00% | – |
| Q3 2018 | $10,000 | 0.0% | 133 | 0.0% | 0.00% | – |
| Q2 2018 | $10,000 | +150.0% | 133 | +64.2% | 0.00% | – |
| Q1 2018 | $4,000 | +300.0% | 81 | +237.5% | 0.00% | – |
| Q4 2017 | $1,000 | – | 24 | +700.0% | 0.00% | – |
| Q3 2017 | $0 | -100.0% | 3 | -97.6% | 0.00% | – |
| Q1 2017 | $8,000 | -11.1% | 125 | -3.1% | 0.00% | – |
| Q4 2016 | $9,000 | -73.5% | 129 | -81.4% | 0.00% | – |
| Q2 2016 | $34,000 | +9.7% | 693 | +43.5% | 0.00% | – |
| Q1 2016 | $31,000 | -70.2% | 483 | -47.7% | 0.00% | – |
| Q4 2015 | $104,000 | +25.3% | 924 | +7.4% | 0.00% | – |
| Q3 2015 | $83,000 | -2.4% | 860 | +2.6% | 0.00% | – |
| Q2 2015 | $85,000 | – | 838 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |